In vitro and in vivo anticancer activities of a novel antibiotic by Xiaoxi, C
African Journal of Biotechnology Vol. 10(41), pp. 8137-8139, 3 August, 2011     
Available online at http://www.academicjournals.org/AJB 
DOI: 10.5897/AJB11.147 














Basic Medicine College, Zhejiang Chinese Medicine University, Binjiang District, Hangzhou City, Zhejiang Province, 
Postcode: 310053, People’s Republic of China. E-mail: chenxiaoxi@hotmail.com. Tel: 0086-0571-86613774. 
 
Accepted 24 March, 2011 
 
IC50 for nine cancer cell lines was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assays. In KM mice bearing sarcoma S180 that was treated with subcutaneous (s.c.) 
injection of antibiotic BS, marked cures were obtained. In terms of tumor weight, the treated/control = 
0.43. The conclusion is that BS merit further investigation as a potential anti-cancer candidate drug. 
 





Global cancer rates could increase by 50% to 15 million 
by 2020 (WHO, 2010). Chemotherapy is one of the 
potent treatments for prolonging the patient’s life (Sirinet, 
2010). Natural products have afforded a rich source of 
compounds that has found many applications in cancer 
chemotherapy. Over 70% of the anticancer compounds 
are either natural products or natural product-derived 
substances (Karikas, 2010) and the therapeutic applica-
tion of microbial metabolites provides the opportunity for 
the discovery of anticancer agent (for example, Diso 
razole A1, doxorubicin, bleomycin, mitomycin, lipopeptide 
and dactinomicines) (Grever, 2001; Elnakady et al., 2004).  
In the process of screening the bacteria that can 
antagonize Xanthomonas oryzae pv. oryzae (a pathogen 
of rice), we happened to obtain a strain of Bacillus sublilis 
(named bacteria BS) that could secret a novel antibiotic 
(named BS). We found that BS had better in vitro 
anticancer activity, so we were interested whether or not 
BS had antitumor potential in vivo. The purpose of the 
paper is to assay the BS’s in vitro anticancer activity via 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) method and to evaluate the BS’s in vivo 




Abbreviations: MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide; s.c, subcutaneous. 
MATERIALS AND METHODS 
 
Culture medium, animal, cell line and microorganism 
 
KMB culture medium 
 
The volume of BBI company peptone (20 g), glycerol (15 ml), 
K2HPO (1.5 g) and MgSO2 (0.75 g), was adjusted to 1000 ml by 
distilled water, sterilized at 121°C for 20 min. Quartz sand was 
immersed in acidic potassium dichromate solution for 24 h to 
oxidize the organic substance (the acidic potassium dichromate 
solution: K2Cr2O7 (37 g) plus 300 ml was heated and stirred until 
potassium dichromate was dissolved). After it was cooled, 300 ml 
(98%) sulphuric acid was gradually added. The quartz sand was 
eluted with distilled water for 10 h to remove metallic ion and 





KM mice (half male and half female, 6 to 8 weeks old, 20 to 25 g) 
were purchased from the National Rodent Laboratory Animal 
Resources, Shanghai Branch, People’s Republic of China.  
 
 
Cell lines  
 
The cells of mouse sarcoma S180 were generously provided by the 
Pharmaceutical Department of Zhejiang Chinese Medicine Univer-
sity, P. R. China. BS-producing-bacterium or bacteria BS (a strain of 
Bacillus subtilis) was isolated from the egg plant leaf derived from 
the suburb of Hangzhou city, Zhejiang province, P. R China. The 
fungus   (Rhizoctonia    solani)    was    generously    given    by  the  




Table 1. Cell growth inhibition by BS against 15 cancer cell lines. 
 
Cell line IC50 (µg/ml) 










The results are expressed as mean from three independent 





Biotechnological Institute of Zhejiang University, P. R. China.  
 
 
Fermentation, BS extraction and purification 
 
At 37°C, for ten days, bacteria BS was cultured on the surface of 
the quartz sand that was immersed in KMB culture medium, while 
the surface of the quartz sand is not covered with the liquid culture 
medium (previous work had shown that bacteria BS could produce 
more BS if it was cultured on the solid medium). Thereafter, the 
quartz sand, which had absorbed BS secreted by bacteria BS, was 
immersed in the water to be distilled. The condensed water was 
collected and passed through active carbon chromatographic 
column, which was then eluted with ether. The eluted ether was left 
at room temperature (25~30°C) overnight to evaporate ether. The 
remainder was chromatographed on silica gel column which was 
eluted with ether. Fraction with the greatest activity was further 
chromatographed on silica gel column and then eluted with normal 
pentane: ether=1:4. The normal pentane and ether were both 
evaporated at room temperature (25 ~ 30°C). In the aforementioned 
purifying process, the bio-activity was tracked by an inhibition zone 
of a fungus (R. solani). The activity was finally confirmed by the 
MTT method (the test cell used was mouse sarcoma S180).  
 
 
Cytotoxicity assays  
 
The inhibitory effect of BS on nine cancer cell lines was assessed in 
a 96-well microtiter plates by measuring MTT dye as described by 
Scudiero DA and Shoemaker RH (Scudiero et al., 1988). However, 
IC50 was determined by the Logit model. 
 
 
In vivo antitumor effects  
 
In vivo antitumor work was performed at the Animal Center of 
Zhejiang Chinese Medicine University, P. R. China. Cells of 
sarcoma S180, 1×10
7
/mL, 200 µl per mouse, were implanted by 
subcutaneously (s.c.), respectively on day 0. Treatments were given 
on days 1, 2, 3, 5, 6 and 7. BS, as well as 5-FU, was respectively 
injected at intervals by s.c., that is, injected at 0, 20, 40, 60, 80, 100 
and 120 min. For each s.c. injection, the dose was 3 mg/kg for SB 
or 6 mg/kg for 5-FU. Tumor volume was measured every other day, 
that is, on day 2, 4, 6, 8, 10, 12 and 14 with vernier, and it was 
calculated by: V = 0.5 × a × b
2 
(a = length, b = width)
 
(Sawaoka et 
al., 1999). After treatment was completed on day 14, all tumors 







Figure 1. The BS’s anticancer efficacy (tumor weight of 






In vitro cytotoxicity 
 
By MTT assay, IC50 for BS against nine cancer cell lines 
H22 was determined, with KB human cancer cell having 
the largest IC50 (24.7) and BEL-7402 human cancer cell 
having the smallest IC50 (0.0076) (Table 1). Thus, the 
difference of IC50 between these two cancer cells was 
more than 3000 times. This meant that different cancer 
cells had different sensitivity to BS.   
 
 
In vivo antitumor activity against sarcoma S180 
 
KM mice bearing sarcoma S180 were treated with BS 
and 5-FU, respectively. Both treatments yielded signifi-
cant therapeutic effects and no mouse died. In the case 
of BS, in terms of tumor weight on day 14, 
treated/control=0.43 (Figure 1), while in the case of 5-FU, 
in terms of tumor weight on day 14, treated/control = 
0.35. After the treatment with BS, tumor weight of 
treated/control = 0.43 while after the treatment with 5-FU, 
tumor weight of treated/control = 0.35 (the figure for 5-FU 





The BS’s in vitro antitumor activity against nine cancer 





BS’s in vivo antitumor activity against sarcoma S180 had 
been confirmed by mouse cancer model. However, all 
mice had survived the effective dosage of BS. These 
indicated that the BS merited further investigation as a 
potential anti-cancer candidate drug.  
BS is a metabolite secreted by a newly isolated B. 
subtilis. B. subtilis is the best-characterized member of 
the gram-positive bacteria (Kunst et al., 1997) and some 
of this strain can produce bioactive substance (U.S. 
environ-mental protection agency, 1997), among which, 
some are anticancer substances (for example, 
lipopeptides, surfactin and glutamines) (Mazza, 1994; 
Kim et al., 2007; Pasupuleti, 2009). However, it has not 
been documented that B. subtilis-derived anticancer 
substance has been developed as a clinical drug. 
Obviously, before B. subtilis-derived anticancer substan-
ces are developed as clinical anticancer drugs, many 
effective anticancer substances should be collected, as 
much as possible, from B. subtilis and more basic 
research should be done. However, the work of this 
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